Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) EBIT (2019 - 2025)

Avidity Biosciences (RNA) has disclosed EBIT for 7 consecutive years, with -$254.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT fell 110.33% year-over-year to -$254.5 million, compared with a TTM value of -$745.9 million through Dec 2025, down 96.85%, and an annual FY2025 reading of -$745.9 million, down 96.85% over the prior year.
  • EBIT was -$254.5 million for Q4 2025 at Avidity Biosciences, down from -$188.8 million in the prior quarter.
  • Across five years, EBIT topped out at -$23.9 million in Q1 2021 and bottomed at -$254.5 million in Q4 2025.
  • Average EBIT over 5 years is -$82.9 million, with a median of -$58.1 million recorded in 2023.
  • The sharpest move saw EBIT crashed 287.92% in 2021, then fell 13.68% in 2023.
  • Year by year, EBIT stood at -$38.5 million in 2021, then crashed by 38.08% to -$53.2 million in 2022, then dropped by 25.4% to -$66.7 million in 2023, then crashed by 81.28% to -$121.0 million in 2024, then plummeted by 110.33% to -$254.5 million in 2025.
  • Business Quant data shows EBIT for RNA at -$254.5 million in Q4 2025, -$188.8 million in Q3 2025, and -$171.1 million in Q2 2025.